Research
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1939 (Published 08 April 2013) Cite this as: BMJ 2013;346:f1939
Related articles
- Clinical Review Published: 17 January 2024; BMJ 384 doi:10.1136/bmj-2022-070856
See more
- NICE approves combination antibody for advanced melanomaBMJ January 10, 2024, 384 q51; DOI: https://doi.org/10.1136/bmj.q51
- Isotretinoin: Regulator adds prescribing safeguards after review of side effectsBMJ November 02, 2023, 383 p2545; DOI: https://doi.org/10.1136/bmj.p2545
- Guidelines should say how much extra time is needed for each patient to implement themBMJ February 06, 2023, 380 p285; DOI: https://doi.org/10.1136/bmj.p285
- Monkeypox can be fatal for people with weak immune systems, CDC warnsBMJ October 28, 2022, 379 o2602; DOI: https://doi.org/10.1136/bmj.o2602
- Cobblestone-like rashes on the penisBMJ October 06, 2022, 379 e070996; DOI: https://doi.org/10.1136/bmj-2022-070996
Cited by...
- Therapeutic advances in rheumatoid arthritis
- Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
- Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis
- How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis
- Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
- Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
- Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
- Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
- Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy
- Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
- Biological therapy for rheumatoid arthritis: is personalised medicine possible?
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
- TNF Inhibitors Are Associated with Higher Risk for Melanoma in Rheumatoid Arthritis Patients